0001302605-14-000001.txt : 20140415 0001302605-14-000001.hdr.sgml : 20140415 20140415215917 ACCESSION NUMBER: 0001302605-14-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140414 FILED AS OF DATE: 20140415 DATE AS OF CHANGE: 20140415 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nova Tina Susan CENTRAL INDEX KEY: 0001302605 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 14766456 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6166 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Nova Bennett Tina DATE OF NAME CHANGE: 20080226 FORMER NAME: FORMER CONFORMED NAME: Nova Tina Susan DATE OF NAME CHANGE: 20040908 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2014-04-14 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001302605 Nova Tina Susan C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 1 0 0 0 Common Stock 2014-04-14 4 M 0 25000 4.11 A 43728 D Common Stock 2014-04-14 4 M 0 10000 6.16 A 53728 D Common Stock 2014-04-14 4 S 0 35000 6.2218 D 18728 D Stock Option (right to buy) 4.11 2014-04-14 4 M 0 25000 0 D 2004-09-14 2014-09-14 Common Stock 25000 0 D Stock Option (right to buy) 6.16 2014-04-14 4 M 0 10000 0 D 2005-01-17 2015-01-17 Common Stock 10000 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.01 and $6.33 per share, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The options were exercisable upon grant, but vested in two equal annual installments beginning on September 14, 2005. The options were exercisable upon grant, but vested monthly over one year. Adam S. Chinnock, as Attorney-in-Fact 2014-04-15